GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sonnet BioTherapeutics Holdings Inc (NAS:SONN) » Definitions » Degree of Operating Leverage

SONN (Sonnet BioTherapeutics Holdings) Degree of Operating Leverage : 0.01 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Sonnet BioTherapeutics Holdings Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Sonnet BioTherapeutics Holdings's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was 0.01. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Sonnet BioTherapeutics Holdings's Degree of Operating Leverage or its related term are showing as below:

SONN's Degree of Operating Leverage is ranked worse than
51.75% of 887 companies
in the Biotechnology industry
Industry Median: -0.02 vs SONN: 0.01

Sonnet BioTherapeutics Holdings Degree of Operating Leverage Historical Data

The historical data trend for Sonnet BioTherapeutics Holdings's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonnet BioTherapeutics Holdings Degree of Operating Leverage Chart

Sonnet BioTherapeutics Holdings Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Degree of Operating Leverage
Get a 7-Day Free Trial - -0.86 -0.66 0.63 0.42

Sonnet BioTherapeutics Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.99 0.67 0.42 -0.01 0.01

Competitive Comparison of Sonnet BioTherapeutics Holdings's Degree of Operating Leverage

For the Biotechnology subindustry, Sonnet BioTherapeutics Holdings's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonnet BioTherapeutics Holdings's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sonnet BioTherapeutics Holdings's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Sonnet BioTherapeutics Holdings's Degree of Operating Leverage falls into.


;
;

Sonnet BioTherapeutics Holdings Degree of Operating Leverage Calculation

Sonnet BioTherapeutics Holdings's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -13.78 (Mar. 2025) / -12.663 (Mar. 2024) - 1 )/( 1 (Mar. 2025) / 0.093 (Mar. 2024) - 1 )
=0.0882/9.7527
=0.01***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Sonnet BioTherapeutics Holdings  (NAS:SONN) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Sonnet BioTherapeutics Holdings Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Sonnet BioTherapeutics Holdings's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonnet BioTherapeutics Holdings Business Description

Traded in Other Exchanges
N/A
Address
100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Executives
John Markey 10 percent owner 10096 RIDGEWOOD DRIVE, TWINSBURG OH 44087
Susan Dexter officer: Chief Technical Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Albert D. Dyrness director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Nailesh Bhatt director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Pankaj Mohan director, officer: Chairman, President and CEO C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Lori Mcneill director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, SUITE 102, PRINCETON NJ 08540
Richard T Kenney officer: Chief Medical Officer C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Donald J. Griffith director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Terence Anthony Rugg officer: Chief Medical Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
John K. Cini officer: Chief Scientific Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Raghu Rao director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Cross John Harry Iii officer: Chief Financial Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Oz Rey Llc 10 percent owner 918 CONGRESS AVENUE, SUITE 100, AUSTIN TX 78701
Mv Amanth Llc 10 percent owner 515 CONGRESS AVE, STE 1400, AUSTIN TX 78701-3516
Robert Sumner Hersch 10 percent owner 515 CONGRESS AVE, STE 1400, AUSTIN TX 78701

Sonnet BioTherapeutics Holdings Headlines

From GuruFocus